Vetter is investing in the expansion of its production capacities in Germany and the USA. The pharmaceutical service provider will relocate its site for development services within the USA and continue to expand there. At the same time, in addition to the ongoing capacity expansions in Ravensburg and Langenargen, Vetter is planning to establish a further site in Saarlouis, Saarland, for the commercial production of authorised medicinal products for market supply. This is the company's response to the increasing global demand for the production of injectable drugs.
“As an independent and family-owned company, we prioritize thoughtful and strategic planning to support our long-term business growth,” shared Senator h.c. Udo J. Vetter, Chairman of the Advisory Board and member of the owner family. “With these investments we reaffirm our commitment on both continents and enable that Vetter Pharma will continue to be part of a growing market in the future.”
For the company, the greater planning security of a future site in Germany is an important decision-making factor. The pharmaceutical service provider's extensive experience with major investment projects in Germany enables a more reliable calculation of costs and realisation times. Vetter can also make better use of the existing infrastructure and continue its co-operation with existing suppliers. The German government has also emphasised the importance of the sector as a key German industry by adopting a national pharmaceutical strategy. With the establishment of Vetter, the Saarland state government is planning to set up a technology park in Saarlouis. Planning for the section-by-section development of the approximately 50-hectare site has already begun at the company. The planned investments amount to several hundred million euros. Production of injectable drugs is set to begin on site from 2030. The pharmaceutical service provider intends to create up to 2,000 additional jobs on site in the coming years.
Managing Director Thomas Otto stated: “After careful consideration, Germany, and Saarland in particular, prove to be the location with the best-fitting conditions for expanding our commercial operations. In addition to the existing and growing competencies and capacities at and around our sites in Ravensburg, we will be able to further expand our range of services. We are taking responsibility for patients and customers worldwide who rely on our high level of quality.”
Vetter's site in Skokie, Illinois, is also benefiting from the positive market development. Like the company's second clinical production site in Rankweil, Vorarlberg, it specialises in projects in early clinical development phases. Both sites continue to develop positively and are experiencing increasing demand. With the planned relocation of the Skokie site to the Des Plaines site acquired a few years ago, Vetter is focussing on the further expansion of its development services.
New buildings for the CDMO, clinical filling and associated services will be constructed on site. The plan is to double the existing capacity in Skokie. The new site also offers space for possible future expansions. “The approval of the Advisory Board aligns with our commitment to meet the long-term capacity needs of our clinical and commercial customers and their patients,” added Managing Director Peter Soelkner. “We know that the multiannual-long investments at our Ravensburg and Langenargen sites will contribute to this, however the market and our customers are in need of even more capacity. We are proud to announce further investments in Des Plaines, IL, USA, and Germany.”
